語系:
繁體中文
English
說明(常見問題)
回圖書館首頁
手機版館藏查詢
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Rewiring Oncogenic Signaling to Ther...
~
Zou, Xinzhi.
FindBook
Google Book
Amazon
博客來
Rewiring Oncogenic Signaling to Therapeutic Viral Activation for Treatment of Metastatic Cancer.
紀錄類型:
書目-電子資源 : Monograph/item
正題名/作者:
Rewiring Oncogenic Signaling to Therapeutic Viral Activation for Treatment of Metastatic Cancer./
作者:
Zou, Xinzhi.
出版者:
Ann Arbor : ProQuest Dissertations & Theses, : 2023,
面頁冊數:
92 p.
附註:
Source: Dissertations Abstracts International, Volume: 85-11, Section: B.
Contained By:
Dissertations Abstracts International85-11B.
標題:
Infections. -
電子資源:
https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31049657
ISBN:
9798382639048
Rewiring Oncogenic Signaling to Therapeutic Viral Activation for Treatment of Metastatic Cancer.
Zou, Xinzhi.
Rewiring Oncogenic Signaling to Therapeutic Viral Activation for Treatment of Metastatic Cancer.
- Ann Arbor : ProQuest Dissertations & Theses, 2023 - 92 p.
Source: Dissertations Abstracts International, Volume: 85-11, Section: B.
Thesis (Ph.D.)--Stanford University, 2023.
Despite recent advances in cancer treatments, improvements to long-term survival in metastatic solid tumors, such as pancreatic or ovarian cancer, remain limited. Current medical therapies suppress growth-promoting biochemical signals or activate immune responses to tumor-associated antigens (TAAs). However, these approaches are limited by toxicity to normal cells that utilize the same signaling pathways or express the same antigens. Previously we developed a method for Rewiring Aberrant Signaling to Effector Release (RASER) to selectively redirect hyperactive ErbB signaling, found in many solid tumors but not normal tissues, to programmable responses. Here in my thesis, I report the engineering of viral vectors that express and are regulated by RASER, resulting in the selective ablation of cancer cells exhibiting hyperactive ErbB signaling. In mice, RASER-restricted vesicular stomatitis virus (VSV) exhibited 10000-fold less toxicity per dose than parental VSV, and 10-fold less than the attenuated VSV-∆M51 variant. RASER-restricted VSV conferred a larger survival benefit in non-immune mouse models of peritoneally disseminated ErbB-hyperactive pancreatic and ovarian cancers. Thus, RASER-restricted viral activation may represent a new approach for treating ErbB-hyperactive metastatic cancers that is independent of adaptive immunity. I also successfully extended the RASER concept to additional signals caused by oncogene mutations including hyperactive c-Met and KRAS and successfully developed Ad and VSV controlled by c-Met and KRAS RASER. With its generalizability and application in vivo,RASER controlled viruses will thus build a completely new type of cancer therapy, in which synthetic proteins are engineered to specifically identify and destroy cancer cells.
ISBN: 9798382639048Subjects--Topical Terms:
1621997
Infections.
Rewiring Oncogenic Signaling to Therapeutic Viral Activation for Treatment of Metastatic Cancer.
LDR
:02958nmm a2200397 4500
001
2404395
005
20241209114621.5
006
m o d
007
cr#unu||||||||
008
251215s2023 ||||||||||||||||| ||eng d
020
$a
9798382639048
035
$a
(MiAaPQ)AAI31049657
035
$a
(MiAaPQ)STANFORDsw016fr9351
035
$a
AAI31049657
040
$a
MiAaPQ
$c
MiAaPQ
100
1
$a
Zou, Xinzhi.
$3
3774710
245
1 0
$a
Rewiring Oncogenic Signaling to Therapeutic Viral Activation for Treatment of Metastatic Cancer.
260
1
$a
Ann Arbor :
$b
ProQuest Dissertations & Theses,
$c
2023
300
$a
92 p.
500
$a
Source: Dissertations Abstracts International, Volume: 85-11, Section: B.
500
$a
Advisor: Lin, Michael;Qi, Stanley;Wang, Bo.
502
$a
Thesis (Ph.D.)--Stanford University, 2023.
520
$a
Despite recent advances in cancer treatments, improvements to long-term survival in metastatic solid tumors, such as pancreatic or ovarian cancer, remain limited. Current medical therapies suppress growth-promoting biochemical signals or activate immune responses to tumor-associated antigens (TAAs). However, these approaches are limited by toxicity to normal cells that utilize the same signaling pathways or express the same antigens. Previously we developed a method for Rewiring Aberrant Signaling to Effector Release (RASER) to selectively redirect hyperactive ErbB signaling, found in many solid tumors but not normal tissues, to programmable responses. Here in my thesis, I report the engineering of viral vectors that express and are regulated by RASER, resulting in the selective ablation of cancer cells exhibiting hyperactive ErbB signaling. In mice, RASER-restricted vesicular stomatitis virus (VSV) exhibited 10000-fold less toxicity per dose than parental VSV, and 10-fold less than the attenuated VSV-∆M51 variant. RASER-restricted VSV conferred a larger survival benefit in non-immune mouse models of peritoneally disseminated ErbB-hyperactive pancreatic and ovarian cancers. Thus, RASER-restricted viral activation may represent a new approach for treating ErbB-hyperactive metastatic cancers that is independent of adaptive immunity. I also successfully extended the RASER concept to additional signals caused by oncogene mutations including hyperactive c-Met and KRAS and successfully developed Ad and VSV controlled by c-Met and KRAS RASER. With its generalizability and application in vivo,RASER controlled viruses will thus build a completely new type of cancer therapy, in which synthetic proteins are engineered to specifically identify and destroy cancer cells.
590
$a
School code: 0212.
650
4
$a
Infections.
$3
1621997
650
4
$a
Ovarian cancer.
$3
3564639
650
4
$a
Plasma.
$3
877619
650
4
$a
Pancreatic cancer.
$3
3704306
650
4
$a
Medical prognosis.
$3
3561728
650
4
$a
Metastasis.
$3
818532
650
4
$a
Toxicity.
$3
3564836
650
4
$a
Reagents.
$3
3683752
650
4
$a
Hyperactivity.
$3
3559054
650
4
$a
Cytotoxicity.
$3
3682273
650
4
$a
Cancer therapies.
$3
3557730
650
4
$a
Viruses.
$3
571474
650
4
$a
Genomes.
$3
592593
650
4
$a
Vectors (Biology).
$3
3691704
650
4
$a
Reproducibility.
$3
3683754
650
4
$a
Cell culture.
$3
604671
650
4
$a
Breast cancer.
$3
3543523
650
4
$a
Behavioral psychology.
$3
2122788
650
4
$a
Biology.
$3
522710
650
4
$a
Cellular biology.
$3
3172791
650
4
$a
Genetics.
$3
530508
650
4
$a
Medicine.
$3
641104
650
4
$a
Oncology.
$3
751006
650
4
$a
Pharmaceutical sciences.
$3
3173021
650
4
$a
Toxicology.
$3
556884
690
$a
0384
690
$a
0306
690
$a
0379
690
$a
0369
690
$a
0564
690
$a
0992
690
$a
0572
690
$a
0383
710
2
$a
Stanford University.
$3
754827
773
0
$t
Dissertations Abstracts International
$g
85-11B.
790
$a
0212
791
$a
Ph.D.
792
$a
2023
793
$a
English
856
4 0
$u
https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31049657
筆 0 讀者評論
館藏地:
全部
電子資源
出版年:
卷號:
館藏
1 筆 • 頁數 1 •
1
條碼號
典藏地名稱
館藏流通類別
資料類型
索書號
使用類型
借閱狀態
預約狀態
備註欄
附件
W9512715
電子資源
11.線上閱覽_V
電子書
EB
一般使用(Normal)
在架
0
1 筆 • 頁數 1 •
1
多媒體
評論
新增評論
分享你的心得
Export
取書館
處理中
...
變更密碼
登入